0000899243-20-007064.txt : 20200304 0000899243-20-007064.hdr.sgml : 20200304 20200304194651 ACCESSION NUMBER: 0000899243-20-007064 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200302 FILED AS OF DATE: 20200304 DATE AS OF CHANGE: 20200304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McMullin David CENTRAL INDEX KEY: 0001738662 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 20689148 MAIL ADDRESS: STREET 1: C/O ALDEYRA THERAPEUTICS, INC. STREET 2: 131 HARTWELL AVENUE, SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-02 0 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001738662 McMullin David C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE LEXINGTON MA 02421 0 1 0 0 Chief Commercial Officer Common Stock 2020-03-02 4 A 0 250000 0.00 A 257703 D Employee Stock Option (Right to Buy) 3.78 2020-03-02 4 A 0 247480 0.00 A 2030-03-01 Common Stock 247480 247480 D Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Includes an additional 1,555 shares of common stock previously acquired under the Issuer's Employee Stock Purchase Plan. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020. /s/ David McMullin 2020-03-04